Quick Answer
Aligos Therapeutics, Inc. reported Total Revenue of $2.19 million for fiscal year 2025.
Aligos Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $2.19M | -39.5% |
| 2024 | $3.61M | -41.7% |
| 2023 | $6.19M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $741.0K | -40.7% | -23.2% |
| June 30, 2025 | $965.0K | -9.0% | +210.3% |
| March 31, 2025 | $311.0K | -55.2% | -75.1% |
| September 30, 2024 | $1.25M | +15.2% | +17.8% |
| June 30, 2024 | $1.06M | -75.3% | +52.9% |
| March 31, 2024 | $694.0K | +395.7% | -36.0% |
| September 30, 2023 | $1.08M | — | -74.7% |
| June 30, 2023 | $4.29M | — | +2967.1% |
- Aligos Therapeutics, Inc. showed a decrease of -39.5% in Total Revenue compared to the prior fiscal year.
- Over the 2023–2025 period, Aligos Therapeutics, Inc.’s total revenue has declined by 64.7% (from $6.19 million to $2.19 million).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: